parrag ian c 201006 phd thesis.pdf
Post on 24-Feb-2018
223 Views
Preview:
TRANSCRIPT
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
1/238
THE DEVELOPMENT OF ELASTOMERIC BIODEGRADABLE POLYURETHANE
SCAFFOLDS FOR CARDIAC TISSUE ENGINEERING
by
Ian C. Parrag
A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy
Graduate Department of Chemical Engineering and Applied Chemistry &
The Institute of Biomaterials and Biomedical Engineering
University of Toronto
Copyright by Ian C. Parrag (2010)
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
2/238
ii
THE DEVELOPMENT OF ELASTOMERIC BIODEGRADABLE POLYURETHANE
SCAFFOLDS FOR CARDIAC TISSUE ENGINEERING
Ian C. Parrag
Doctor of Philosophy, 2010
Department of Chemical Engineering and Applied Chemistry & Institute of Biomaterials and
Biomedical Engineering, University of Toronto
Abstract
In this work, a new polyurethane (PU) chain extender was developed to incorporate a
Glycine-Leucine (Gly-Leu) dipeptide, the cleavage site of several matrix metalloproteinases.
PUs were synthesized with either the Gly-Leu-based chain extender (Gly-Leu PU) or a
phenylalanine-based chain extender (Phe PU). Both PUs had high molecular weight averages
(Mw > 125,000 g/mol) and were phase segregated, semi-crystalline polymers (Tm ~ 42C) with
a low soft segment glass transition temperature (Tg < -50C). Uniaxial tensile testing of PU
films revealed that the polymers could withstand high ultimate tensile strengths (~ 8-13 MPa)
and were flexible with breaking strains of ~ 870-910% but the two PUs exhibited a significant
difference in mechanical properties.
The Phe and Gly-Leu PUs were electrospun into porous scaffolds for degradation and
cell-based studies. Fibrous Phe and Gly-Leu PU scaffolds were formed with randomly organizedfibers and an average fiber diameter of approximately 3.6 m. In addition, the Phe PU was
electrospun into scaffolds of varying architecture to investigate how fiber alignment affects the
orientation response of cardiac cells. To achieve this, the Phe PU was electrospun into aligned
and unaligned scaffolds and the physical, thermal, and mechanical properties of the scaffolds
were investigated.
The degradation of the Phe and Gly-Leu PU scaffolds was investigated in the presence of
active MMP-1, active MMP-9, and a buffer solution over 28 days to test MMP-mediated and
passive hydrolysis of the PUs. Mass loss and structural assessment suggested that neither PU
experienced significant hydrolysis to observe degradation over the course of the experiment.
In cell-based studies, Phe and Gly-Leu PU scaffolds successfully supported a high
density of viable and adherent mouse embryonic fibroblasts (MEFs) out to at least 28 days.
Culturing murine embryonic stem cell-derived cardiomyocytes (mESCDCs) alone and with
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
3/238
iii
MEFs on aligned and unaligned Phe PU scaffolds revealed both architectures supported adherent
and functionally contractile cells. Importantly, fiber alignment and coculture with MEFs
improved the organization and differentiation of mESCDCs suggesting these two parameters are
important for developing engineered myocardial constructs using mESCDCs and PU scaffolds.
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
4/238
iv
Acknowledgments
There are numerous people who have contributed to my scientific and personal
experiences during the last several years that have made this work possible. It is my hope that I
have thanked the people who have helped me along the way because I would not have made it
far enough to be writing this now without their help. I would first like to thank my supervisor
Dr. Kimberly Woodhouse for her guidance and support that have been invaluable for my career
development. I am very appreciative of the flexibility she has given me in pursuing my research
and personal interests. Without the opportunity to work with her, I would not have been able to
do and accomplish many things that are important to me. I would also like to thank my
committee members, Dr. Paul Santerre and Dr. Peter Zandstra, for their time and guidance with
this research project along with access to their lab equipment and resources. The members of the
Santerre, Zandstra, and Edwards labs have been very helpful in the training and use of lab
equipment and technical advice. Celine Bauwens, Sylvia Niebruegge, Ting Yin, Kuihua Cai,
and Cheryl Washer have been particularly accommodating in this regard. I would also like to
acknowledge Eric Altman, Frank Gibbs, Dionne White, Gary Skarja, and Tim Burrows for
technical consultations and sample analysis. Funding from the Department of Chemical
Engineering and Applied Chemistry and OGSST was much appreciated. It has been a realpleasure to work with all of the members of the Woodhouse group both in and out of the lab. I
would especially like to thank Joanna Fromstein, Patrick Blit, Cecilia Alperin-Dalley, Robin
Farmer, Lauren Flynn, Dave Laughren, and Elizabeth Srokowski for all their help with the work
in this thesis. Lastly, I would like to thank my family and friends for all their support and
encouragement that has gotten me through the difficult and enjoyable times that have come along
with this research project. Things never seem that bad when youve got good people in your life
and I am very appreciative of every single one of them.
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
5/238
v
Table of Contents
Chapter 1: Introduction...1
1.0. Clinical Problem......1
1.1. Hypothesis....2
1.2. Research Objectives.3
1.3 References3
Chapter 2: Literature Review..5
2.0. Introduction......5
2.1 Heart Tissue....5
2.1.1 Myocardial Cells.6
2.1.2. Extracellular Matrix Organization and Function.8
2.1.3. Reparative Response of the Heart to Myocardial Infarctions..9
2.2. Matrix Metalloproteinases and their Role in Heart Remodeling and Disease...10
2.2.1. MMP Expression Following Myocardial Infarctions and in Heart Failure...11
2.2.2. Cleavage Sites of ECM Proteins, Peptides and Biomaterials by MMPs...12
2.3. Regenerative Approaches to Repair the Heart...142.3.1. Inducing Endogenous Mechanisms in Heart Repair..14
2.3.2. Cellular Cardiomyoplasty..15
2.3.2.1. Fetal and Neonatal Cardiomyocytes....17
2.3.2.2. Embryonic Stem Cell-Derived Cardiomyocytes.....18
2.3.2.2.1. Differentiation of Murine Embryonic Stem Cells into Cardiomyocytes...19
2.3.2.2.2. Large-Scale Production of a Pure Population of Embryonic Stem Cell-Derived
Cardiomyocytes.21
2.3.2.2.3. Transplantation of Human and Murine ESC-Derived Cells into the Heart...23
2.3.3. Cardiac Tissue Engineering...25
2.3.3.1. Myocardial Tissue Engineering Using Biomaterials with Undefined Structures....25
2.3.3.2. In SituCardiac Tissue Engineering......27
2.3.3.3. Myocardial Cell Sheets....29
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
6/238
vi
2.4. Cardiac Tissue Engineering Using Pre-formed Three-Dimensional Scaffolds.31
2.4.1. Biomaterials for Cardiac Tissue Engineering31
2.4.1.1. Natural Biomaterials....33
2.4.1.2. Synthetic Biomaterials.....33
2.4.1.2.1. Traditional Polymers for Tissue Engineering...33
2.4.1.2.2. Elastomeric Biomaterials..34
2.4.2. Scaffold Fabrication Techniques...36
2.4.3. Cells for Cardiac Tissue Engineering38
2.4.4. Seeding and Cultivation Parameters for Cardiac Tissue Engineering...39
2.5. Biodegradable Segmented Polyurethanes for Tissue Engineering41
2.5.1. Chemistry and Properties of Degradable Polyurethanes...41
2.5.1.1. Segmented Polyurethane Synthesis.43
2.5.1.2. Reactant Chemistry for Biodegradable Polyurethanes44
2.5.2. Polyurethane Degradation.48
2.5.3. Enzyme-Degradable Polyurethanes..51
2.6. Electrospinning for Tissue Engineering Scaffold Formation54
2.6.1. Principles and Parameters..54
2.6.2. Electrospun Scaffolds for Cardiac Tissue Engineering.56
2.7. References..58
Chapter 3: Synthesis and Characterization of Phe and Gly-Leu-containing Segmented
Polyurethanes...84
3.0. Abstract..84
3.1. Introduction85
3.2. Materials and Methods...86
3.2.1. Dipeptide-based Chain Extender Synthesis...86
3.2.2. Gly-Leu-based Chain Extender Purification..88
3.2.3. Chain Extender Characterization...89
3.2.4. Polyurethane Synthesis and Film Casting..90
3.2.5. Polyurethane Characterization...91
3.3. Results and Discussion..92
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
7/238
vii
3.3.1. Chain Extender Synthesis and Purification92
3.3.1.1. Reaction Systems for Chain Extender Synthesis.93
3.3.1.2. Synthesis of Chain Extenders using Gly-Ile or Gly-Leu Dipeptides...96
3.3.1.3. Purification Strategies for the Gly-Leu-based Chain Extender...99
3.3.2. Polyurethane Characterization ...106
3.3.2.1. Molecular Weight Averages .106
3.3.2.2. Thermal Transitions and Phase Segregation..107
3.3.2.3. Chemical Composition...107
3.3.2.4. Mechanical Properties109
3.3.2.5. Effect of Amino Acid and Dipeptide-based Chain Extenders on Polyurethane
Properties...110
3.4. Conclusions..112
3.5. References113
Chapter 4: Electrospinning Phe and Gly-Leu Polyurethanes..116
4.0. Abstract116
4.1 Introduction..117
4.2. Materials and Methods.118
4.2.1. Electrospinning Phe and Gly-Leu Polyurethane Scaffolds..118
4.2.2. Scaffold Characterization.120
4.3. Results and Discussion121
4.3.1. Electrospinning Polyurethane Scaffolds..121
4.3.1.1. Effect of PU Concentration on Scaffold Morphology...123
4.3.1.2. Molecular Weight Averages and Thermal Properties129
4.3.1.3. Fiber Size in Electrospun PU Scaffolds for Soft Tissue Engineering...129
4.3.2. Aligned and Unaligned Phe PU Scaffolds...130
4.3.2.1. Scaffold Morphology.131
4.3.2.2. Molecular Weight Averages and Thermal Properties134
4.3.2.3. Mechanical Properties135
4.3.2.4. Electrospun PU Scaffolds for Cardiac Tissue Engineering...138
4.4. Conclusions..141
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
8/238
viii
4.5. References142
Chapter 5: Polyurethane Degradation by Matrix Metalloproteinases146
5.0. Abstract146
5.1. Introduction..146
5.2. Materials and Methods.147
5.2.1. Activation and Activity of MMPs147
5.2.2. Degradation of Polyurethanes by MMPs.149
5.3. Results and Discussion150
5.3.1. Activation of MMPs150
5.3.2. Activity of MMPs after Incubation with Polyurethanes..153
5.3.3. Degradation of Polyurethanes by MMPs.155
5.4. Conclusions..166
5.5. References166
Chapter 6: Cell Response to Electrospun Polyurethane Scaffolds...170
6.0. Abstract170
6.1. Introduction..171
6.2. Materials and Methods.172
6.2.1. Mouse Embryonic Fibroblast Culture and Seeding onto Polyurethane Scaffolds...172
6.2.2. Characterization of MEFs on Phe and Gly-Leu-containing Polyurethanes.172
6.2.3. Culture and Differentiation of Murine Embryonic Stem Cells174
6.2.4. Monitoring the Differentiation of Cardiomyocytes from mESCs...175
6.2.5. Scaffold Preparation and Cell Seeding176
6.2.6. Characterization of mESCDCs and MEFs on Aligned and Unaligned Polyurethane
Scaffolds..176
6.3. Results and Discussion178
6.3.1. Viability of MEFs on Phe and Gly-Leu-containing Polyurethanes.178
6.3.2. Differentiation of mESCs into Cardiomyocytes in Spinner Flasks.181
6.3.3. Effect of Fiber Alignment and Coculture with MEFs on Response of
mESC-derived Cardiomyocytes..187
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
9/238
ix
6.3.4. Aligned and Unaligned PU Scaffolds for Cardiac Tissue Engineering...200
6.4. Conclusions..203
6.5. References203
Chapter 7: Conclusions209
7.0. Conclusions.209
7.1. Significant Contributions to Literature214
7.2. Future Work.214
7.2.1. Polyurethane Design and Synthesis.214
7.2.2. PU Scaffold Formation and Characterization..214
7.2.3. PU Degradation215
7.2.4. Cell-based Testing of PU Scaffolds.215
7.3. References217
Appendix A: Supplementary Information for Dipeptide-based Chain Extender
Characterization220
A.1. C13
NMR Spectra of Reactants, Theoretical Predictions, and Raw Products.220
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
10/238
x
List of Figures
Figure 2.1. The structure of the myocardium.........7
Figure 2.2. The cardiac extracellular matrix..8
Figure 2.3. Alterations in MMP and TIMP levels in human heart disease..............12
Figure 2.4. Illustration of microphase separation in segmented polyurethanes...42
Figure 2.5. Standard two-step segmented polyurethane reaction.....44
Figure 2.6. Diisocyanates used to synthesize biodegradable PUs46
Figure 2.7. Polyols often used in biodegradable PU synthesis47
Figure 2.8. Model for environmental biodegradation of PUs..49
Figure 2.9. Schematic of electrospinning apparatus.55
Figure 3.1. Chain extender reaction system setups..87
Figure 3.2. Synthesis scheme for Gly-Leu-based diester, diamine chain extender..............88
Figure 3.3. Synthesis scheme for Gly-Leu PU.....91
Figure 3.4. Mass spectrum of raw Gly-Ile-CDM-PTSA product.....94
Figure 3.5. Mass spectra of raw Gly-Ile-based chain extender products synthesized indifferent solvent systems....95
Figure 3.6. Mass spectrum of crude product from Gly-Leu-CDM-PTSA...97
Figure 3.7. Mass spectra of Gly-Leu-based chain extender using different catalysts and
diol linkers.....98
Figure 3.8. HPLC separation of Gly-Leu-based diester product using analytical column
and low pH aqueous mobile phase..100
Figure 3.9. HPLC separation of Gly-Leu-based diester product using analytical column
and high pH aqueous mobile phase.101
Figure 3.10. Preparative column HPLC purification of chain extender using low and highpH aqueous mobile phases..102
Figure 3.11. C13
NMR spectra of products collected from preparative column HPLC using
the two developed methods of separation104
Figure 3.12. FT-IR spectrum of purified Gly-Leu-based chain extender ...105
Figure 3.13. The chemical structure of the Phe and Gly-Leu-based chain extenders..106
Figure 3.14. FT-IR analysis of Phe and Gly-Leu PUs.108
Figure 3.15. Representative stress-strain curve for Phe and Gly-Leu PU films..109
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
11/238
xi
Figure 4.1. Illustration of electrospinning apparatus..119
Figure 4.2. A comparison of electrospun Phe PU mats formed in the Rabolt laboratoryand in our laboratory using conditions established in the Rabolt laboratory...122
Figure 4.3. Comparison of Phe PU scaffolds formed before and after optimizing
electrospinning parameters..123Figure 4.4. SEM images of Phe and Gly-Leu PU scaffolds electrospun from different
concentrations.....124
Figure 4.5. Fiber diameter distributions of the Phe and Gly-Leu PU scaffolds electrospun
from varying concentrations126
Figure 4.6. Comparison of structural features of the Phe and Gly-Leu PU scaffolds usedfor degradation and cell-based studies.128
Figure 4.7. SEM images of aligned and unaligned Phe PU scaffolds132
Figure 4.8. Characteristics of aligned and unaligned Phe PU scaffolds.133
Figure 4.9. Representative stress-strain curves for aligned and unaligned PU scaffolds
stretched in preferred and cross-preferred directions of orientation136
Figure 5.1. Activation of MMPs using APMA..151
Figure 5.2. Zymogram of MMP activation solutions.152
Figure 5.3. Activity of MMPs after incubation with PU scaffolds154
Figure 5.4. Mass remaining of PU scaffolds over 28 day degradation study.156
Figure 5.5. SEM images of PU scaffolds after 28 day incubation period in various
solutions...157
Figure 5.6. Reaction scheme for enzyme activity assay and competitive substrate
enzyme activity assay..161
Figure 5.7. Inhibition of FS-6 cleavage using the Gly-Leu dipeptide....161
Figure 5.8. Water uptake by Phe and Gly-Leu PU scaffolds.164
Figure 6.1. Illustration of experimental details for cardiomyocyte production and cell
seeding.175
Figure 6.2. AlamarBlue
analysis of MEFs on PU scaffolds over 28 day period.....179
Figure 6.3. Staining of MEFs on PU scaffolds and TCPS.....180
Figure 6.4. Total cell number in spinner flasks during differentiation of mESCs intocardiomyocytes....184
Figure 6.5. EB characteristics during differentiation of mESCs into cardiomyocytes..185
Figure 6.6. Flow cytometry of cells before and after differentiation in spinner flasks..187
Figure 6.7. AlamarBlue
analysis of cell-seeded PU constructs of varying architecture
and TCPS controls...189
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
12/238
xii
Figure 6.8. Live/Dead
staining of cells on Phe PU scaffolds of varying architecture at
day 18+6..191
Figure 6.9. Immunostaining of cells on aligned and unaligned PU scaffolds192
Figure 6.10. Immunostaining of cardiac constructs with mESCDCs showing varying
levels of differentiation....193Figure 6.11. Quantifying the alignment of cells on PU scaffolds in coculture constructs...197
Figure 6.12. Gap junction staining of mESCDCs and MEFs in coculture on aligned andunaligned PU scaffolds199
Figure A.1. C13
NMR spectrum of Gly-Leu dipeptide220
Figure A.2. C13
NMR spectrum of CDM221
Figure A.3. Theoretical predictions of Gly-Leu-based diester chain extender using
ACD i-Lab software.221
Figure A.4. C
13
NMR spectrum of raw Gly-Leu-CDM-PTSA...222
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
13/238
xiii
List of Tables
Table 2.1. List of cell types considered for cardiac repair..16
Table 2.2. Summary of biomaterials and their applications in cardiac tissue engineering.....32
Table 2.3. Summary of electrospinning parameters and effects on fiber morphology...56
Table 3.1. Molecular weight averages for PUs containing Phe and Gly-Leu-based chain
extenders..107
Table 3.2. Thermal properties of the Phe and Gly-Leu PUs as determined by DSC107
Table 3.3. Summary of mechanical properties of PU films..110
Table 4.1. GPC and DSC results of Phe and Gly-Leu PU films and scaffolds.....129
Table 4.2. GPC and DSC results for Phe PU films and electrospun scaffolds of varyingarchitecture...134
Table 4.3. Summary of mechanical properties of aligned and unaligned PU scaffolds
stretched in preferred and cross-preferred directions of orientation136
Table 4.4. Mechanical properties of films of investigated or potential synthetic
biomaterials in cardiac tissue engineering...141
Table 6.1. Assessment of cell shape and sarcomere formation of mESCDCs..194
Table 6.2. Assessment of mESCDC dimensions......195
Table 6.3. Average angle of cell axis and orientation index.198
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
14/238
xiv
List of Abbreviations
3-D three-dimensional
ACN acetonitrile
ANP atrial natriuretic peptide
APMA 4-aminophenylmercuric acetate
BMP bone morphogenic protein
BV blood vessels
CB cardiac body
CDM 1,4-cyclohexane dimethanol
cTnT cardiac isoform of troponin T
Cx-43 connexin-43
DAPI 4',6-diamidino-2-phenylindole
DCM dichloromethane
DMEM Dulbeccos modified eagles medium
Dnp fluorescence-quenching group; 2,4-dinitrophenyl
DSC differential scanning calorimetry
E initial modulus; Youngs modulus; elasticity; stiffness
EB embryoid body
ECM extracellular matrix
EHT engineered heart tissue
ESC embryonic stem cell
ESI electrospray ionization
FACS fluorescent activated cell sorting
FBGC foreign body giant cell
FBS fetal bovine serum
FS-6 fluorogenic substrate for MMPs; Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2
FT-IR Fourier transform infrared
G418 geneticin; a neomycin analog
G-CSF granulocyte colony stimulating factor
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
15/238
xv
GFP green fluorescent protein
Gly glycine
Gly-Leu PU segmented polyurethane composed of PCL of molecular weight 1250, LDI, and a
Gly-Leu-based chain extender
GPC gel permeation chromatography
hESC human embryonic stem cell
hESCDC human embryonic stem cell-derived cardiomyocyte
HPLC high performance liquid chromatography
HOCl hypochlorous acid
LDI lysine-based diisocyanate
Leu leucine
LIF leukemia inhibitory factor
Mca fluorescent molecule; (7-methoxycoumarin-4-yl)acetyl
MDM monocyte-derived macrophage
mESC mouse embryonic stem cell
mESCDC mouse embryonic stem cell-derived cardiomyocyte
MHC myosin heavy chain
MHC-neor transgene carrying neomycin resistance gene driven by -myosin heavy chain
promoter
MI myocardial infarction
MLC-2v myosin light chain-2v
MMP matrix metalloproteinase
NMR nuclear magnetic resonance
ONOO-
peroxynitrite
PBS phosphate buffered saline solution
PCL1250 polycaprolactone diol of molecular weight 1250 g/mol
PGA poly(glycolic acid)
PGS poly(glycerol sebacate)
Phe phenylalanine
Phe PU segmented polyurethane composed of PCL of molecular weight 1250, LDI, and a
Phe-based chain extender
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
16/238
xvi
pGK-hygror transgene carrying hygromycin resistance gene driven by phosphoglycerate kinase
promoter
PIPAAm poly (N-isopropylacrylamide)
PLA poly(lactic acid)
PLGA poly(lactic-co-glycolic acid)
PMN neutrophils; polymorphonucleocytes
PTSA p-toluene sulfonic acid
PU polyurethane
SDS sodium dodecyl sulfate
TCPS tissue culture polystyrene
TFA trifluoroacetic acid
Tg glass transition temperature
TGF transforming growth factor
TIPS thermally induced phase separation
Tm melting temperature
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
17/238
1
Chapter 1: Introduction
1.0 Clinical Problem
Heart disease is one of the leading causes of disability and death in industrialized nations.
In the most recent study in Canada in 1998 (with updates in 2004), it was found that
cardiovascular diseases affect a quarter of the Canadian population accounting for more than a
third of the deaths and placing an estimated $18 billion burden on the Canadian economy [1, 2].
Topping the list of cardiovascular diseases was coronary heart disease, which leads to ischemic
heart disease, acute myocardial infarctions and congestive heart failure. Similarly, the
prevalence of cardiovascular diseases in the United States in 2005 was 80.7 million, or
approximately 37% of the population. These cases cost the U.S. health care system $448.5billion and resulted in 869,700 deaths (36.3% of all deaths) [3]. Furthermore, 8.1 million
individuals in the U.S. suffer from the debilitating affects of a myocardial infarction with more
than 920,000 new or recurring cases and 156,800 fatalities in 2004. Interestingly, successes in
treating myocardial infarctions and other cardiac diseases have allowed individuals with
damaged hearts to live longer, but is leading to an increase in the prevalence of congestive heart
failure [2]. In the U.S. alone, 5.3 million people suffer from congestive heart failure with
284,400 deaths in 2004. As a consequence, these studies indicate the huge health care burden of
heart disease and identify the need for effective treatments to combat it.
The heart has a limited capacity to regenerate on its own. Cardiomyocytes that are lost
due to a myocardial infarction (MI), if not fatal, are replaced by the formation of scar tissue, an
adaptive response leading to the loss of contractile function [4]. Subsequent remodeling events
occur in the heart to compensate for this loss of contractile function in an attempt to maintain
cardiac output. Some of these events include changes in cell type, extracellular matrix
composition and organization, ventricular size and architecture, neurohormonal signaling, gene
and protein expression, and paracrine signaling, to name but a few [5]. In the short term, these
remodeling events attempt to maintain cardiac performance but inevitably become destructive to
the heart causing congestive heart failure and ultimately death.
There currently exists several treatment options following a MI and in congestive heart
failure. Pharmacological agents, such as thrombolytic agents, antithrombotics, nitrates, -
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
18/238
2
blockers, Ca+2 channel blockers, angiotensin converting enzyme inhibitors, statins, and
adrenoceptor antagonists are typically used to increase blood flow, limit the ventricular
remodeling events, and increase cardiac output [6]. Although this therapy may be effective in
temporarily warding off heart failure, it is generally used to manage patients and offers little in
the way of treating the root of the condition. A second form of treatment employs the use of
mechanical devices, such as the left ventricular assist device. This treatment option has
traditionally been used as a bridge-to-transplantation, but has gained wider use as a destination
therapy and as a bridge-to-recovery option [7]. By reducing the workload of the injured heart,
LVAD therapy allows reverse remodeling to occur, whereby the destructive changes occurring in
the heart during remodeling are reversed [8]. This is an exciting new treatment option with some
patients undergoing sufficient recovery for the mechanical device to be removed, but the number
of patients eligible for this therapy remains low. A third treatment option, which remains the
gold standard because the recipient often regains full cardiac function, is heart transplantation.
This option, however, is limited by the lack of suitable donors and has motivated the field of
regenerative medicine to find alternatives that repair, replace, or augment the heart to restore
cardiac functionality.
There are many promising new approaches that are currently being investigated to
regenerate injured myocardial tissue and help fight heart disease. Some of these approaches
include pharmacological strategies, protein and peptide-based methods, gene therapy, cell-based
techniques, and tissue engineering [9]. Cardiac tissue engineering, in particular, offers the
advantage of combining several of these beneficial regenerative techniques along with novel
biomaterials and holds tremendous potential in the treatment of heart disease. As research in
cardiac tissue engineering continues to move forward, so to does the potential of easing the
enormous social and economic burden of this disease.
1.1 Hypothesis
The project hypothesis is defined in two parts: 1) glycine-leucine (Gly-Leu) containingbiodegradable segmented polyurethanes can act as temporary scaffolds that support cells; and 2)
fiber alignment within polyurethane scaffolds influences the orientation response of murine
embryonic stem cell-derived cardiomyocytes and mouse embryonic fibroblasts seeded on the
constructs.
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
19/238
3
1.2 Research Objectives
1) Synthesize and characterize a family of biodegradable, segmented polyurethanes using a
Gly-Leu-based diester chain extender, lysine-based diisocyanate, and polycaprolactone
diol
2)
Develop and characterize porous, three-dimensional biodegradable polyurethane
scaffolds by electrospinning and investigate the effects electrospinning has on scaffold
and polymer properties
3) Evaluate the in vitro degradation of amino acid and dipeptide-containing polyurethane
scaffolds in the presence of matrix metalloproteinase-1 and matrix metalloproteinase-9
4) Characterize the in vitrocellular response of cells seeded on polyurethane scaffolds
a) Assess the viability of mouse embryonic fibroblasts seeded on Phe and Gly-Leu-
containing polyurethane scaffolds
b) Characterize the response of murine embryonic stem cell-derived cardiomyocytes
and mouse embryonic fibroblasts on aligned and unaligned Phe-containing
polyurethane scaffolds
1.3 References
1. Heart and Stroke Foundation of Canada, Statistics and Background Information -Incidence of Cardiovascular Diseases.1998.
2. Heart and Stroke Foundation of Canada, Statistics. 2008.
3. American Heart Association,Heart disease and stroke statistics - 2008 update.AmericanHeart Association, 2008.
4. Kumar, V., R.S. Cotran, and S.L. Robbins,Basic Pathology. 7th ed. 2003, Philadelphia:Saunders. xii, 873.
5. Swynghedauw, B.,Molecular mechanisms of myocardial remodeling.PhysiologicalReviews, 1999. 79(1): p. 215-262.
6. Gelfand, E.V. and C.P. Cannon,Myocardial infarction: contemporary management
strategies.Journal Of Internal Medicine, 2007. 262(1): p. 59-77.
7. Deng, M.C., L.B. Edwards, M.I. Hertz, A.W. Rowe, B.M. Keck, R. Kormos, D.C. Naftel,J.K. Kirklin, and D.O. Taylor,Mechanical circulatory support device database of theInternational Society for Heart and Lung Transplantation: Third Annual Report - 2005.Journal Of Heart And Lung Transplantation, 2005. 24(9): p. 1182-1187.
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
20/238
4
8. Burkhoff, D., S. Klotz, and D.M. Mancini,LVAD-Induced reverse remodeling: Basic andclinical implications for myocardial recovery.Journal Of Cardiac Failure, 2006. 12(3): p.227-239.
9. Puceat, M., Pharmacological approaches to regenerative strategies for the treatment ofcardiovascular diseases.Current Opinion In Pharmacology, 2008. 8(2): p. 189-192.
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
21/238
5
Chapter 2: Literature Review
2.0 Introduction
The high prevalence and economic burden of myocardial infarctions, congestive heart
failure, and other heart diseases has motivated researchers and clinicians to develop new
strategies to treat patients. Tissue engineering is a field that seeks the development of tissue
constructs to repair, replace, or augment damaged or diseased tissues. This field has already had
some clinical successes that demonstrate how tissue engineering may revolutionize the way
clinicians approach disease management and therapy [1-3]. The first tissue engineered trachea
transplant, for example, was recently performed using a decellularized human donor trachea
combined with the patients epithelial and mesenchymal stem cell-derived chondrocytes [1].This novel procedure not only prevented the need to remove the diseased lung, the conventional
treatment choice, but also eliminated the need for immunosuppression therapy and drastically
improved the quality of life compared to the pre-operation condition and lung-resection option.
The heart is a complex organ composed of many critical components that give rise to its
unique function but also renders it susceptible to various injuries and diseases. Cardiovascular
tissue engineering on a whole explores tissue substitutes for the various components of the heart,
such as blood vessels, heart valves, and cardiac muscle. Advances in cardiovascular tissue
engineering have been made for each of the different components of the heart, but the
development of fully functional cardiac muscle remains one of the most challenging aspects of
this field.
2.1 Heart Tissue
The heart is a muscular organ responsible for circulating blood throughout the body. It is
composed of four muscular chambers, the right and left atria, which pump blood to the
ventricles, and the right and left ventricles, which pump blood to the pulmonary and systemic
circuits respectively. Critical to this pumping function is the heart wall. The heart wall is
composed of three distinct layers, the endocardium, myocardium, and epicardium, respectively
located from the lumen of each cardiac chamber out, all surrounded by the pericardium [4].
While each layer plays a critical role for normal cardiac function, the myocardium is the
contractile portion that generates the necessary forces to pump blood to the body and constitutes
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
22/238
6
the bulk of the heart wall. The myocardium consists of multiple interlocking layers of cardiac
muscle tissue and the associated blood vessels, connective tissue, and nerves (Figure 2.1). Cells
within each layer of cardiac muscle tissue are anisotropically organized parallel to each other and
each layer is subsequently oriented at different angles depending on chamber type and location
within each chamber [4]. Due to the high energy requirements associated with contraction, the
myocardium is a highly vascularized structure [4]. The high demand for oxygen within this
muscular layer, however, renders it susceptible to ischemic injury. Disruption of the normal
tissue composition and organization of this portion of the heart wall is observed in many diseases
leading to a loss of contractile function. As a result, regenerative medicine techniques target the
myocardium in an attempt to restore contractility to the tissue. Understanding the cellular
components and tissue organization in the myocardium is therefore a requisite for the design of
engineered myocardial constructs.
2.1.1 Myocardial Cells
The myocardium is composed of several cell types including vascular endothelial cells,
vascular smooth muscle cells, fibroblasts, neurons, and cardiomyocytes [5]. Cardiomyocytes are
the contractile cells taking up the bulk of the space in the myocardium. Mature adult ventricular
cardiomyocytes are rod-shaped, typically 10-30 m in diameter and 80-150 m in length [5], and
contain a high number of mitochondria and myoglobin to meet the energy requirements of
contraction [4]. Cardiomyocytes are composed primarily of bundles of myofibrils. Myofibrils
consist of a long repeated chain of sarcomeres, the basic contractile unit that give the cells a
striated appearance, composed of actin, myosin, tropomyosin, the troponin complex, and other
associated proteins [6]. In a resting state, the troponin complex and tropomyosin prevent myosin
from interacting with actin filaments. In response to a propagating action potential, the
excitation-contraction coupling mechanism causes an increase in intracellular Ca2+
concentration, the removal of the tropomyosin protein barrier, and, in the presence of ATP,
allows myosin to bind to actin leading to sarcomere shortening [6]. The excitation-contractioncoupling mechanism is made possible by the unique plasma membrane within these cells, the
sarcolemma, along with the transverse tubular system, the sarcoplasmic reticulum, and numerous
protein pumps, ion channels, and regulatory proteins. All working in a coordinated fashion, the
action potential, initiated independently of the nervous system, triggers this complex mechanism
ultimately leading to cardiomyocyte contraction.
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
23/238
7
Individual cardiomyocytes contracting on their own, however, does little in generating
the required forces to pump blood to the body. A coordinated effort is required and as such,
cardiomyocytes are organized into multiple interlocking layers connected to neighboring cells at
intercalated discs unique to cardiac muscle (Figure 2.1) [4]. At intercalated discs, cells are
electromechanically coupled by desmosomes, fascia adherens junctions, and gap junctions [7].
Because of the mechanical, chemical, and electrical connections between cardiomyocytes, the
cardiac tissue acts as a functional syncytium providing synchronous contraction and effective
force production to pump blood from the heart chambers.
Figure 2.1: The structure of the myocardium: a) histology image showing multiple interlocking layers of
cardiomyocytes with arrows indicating intercalated discs. b) Schematic identifying organization of bundles of
cardiomyocytes, fibroblasts, blood vessels (BV), and extracellular matrix. Images used with permission from Dr.
Caceci [8].
Cardiac fibroblasts are the most numerous cells in the myocardium, and they play a
pivotal role in regulating tissue organization and function [9]. Fibroblasts are organized adjacent
to groups of myocytes where they interact with other fibroblasts, myocytes, and extracellular
matrix (ECM) macromolecules (Figure 2.1b) [10]. Cardiac fibroblasts are electrically connected
to adjacent fibroblasts and cardiac myocytes via gap junctions that aid in signaling between cells
[10]. The predominant role of cardiac fibroblasts, however, is to regulate the structure and
function of the ECM through deposition of its constituents and secretion of enzymes that degrade
them. The extracellular matrix acts as a mechanical support for tissues and transmits information
from the extracellular environment to regulate cell shape and function. Fibroblasts synthesize
and deposit the majority of the cardiac ECM, especially fibrillar collagen types I and III, elastin,
the proteoglycans laminin and fibronectin, and glycosaminoglycans [5, 11, 12]. ECM
remodeling and turnover is carried out by matrix metalloproteinases secreted by the fibroblasts in
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
24/238
8
both physiological and pathological states. Several growth factors, cytokines, and other
bioactive molecules are also produced by cardiac fibroblasts highlighting their regulatory role in
the heart [9]. In light of their important function in the myocardium, there is an increasing body
of evidence suggesting the critical role of cardiac fibroblasts and other non-myocytes in the
development of engineered cardiac tissue. This will be discussed in further detail in section
2.4.3.
2.1.2 Extracellular Matrix Organization and Function
The myocardial extracellular matrix is made up of a fibrillar collagen network, basement
membranes, elastic fibers, proteoglycans, glycosaminoglycans and a variety of bioactive
signaling molecules (Figure 2.2a) [13]. This ECM is subdivided into three groups: the
endomysium, which surrounds individual myocardial cells; the perimysium, which surrounds
groups of myocytes; and the epimysium surrounding the entire muscle [14]. The specific
organization of the ECM layers aid in proper function of the tissue and relay important signaling
cues to the cardiac cells during normal physiology and disease.
Figure 2.2: Cardiac extracellular matrix: a) components and b) organization of endomysium and perimysium.
Images used with permission from MacKenna et al. [15] and Goldsmith and Borg [16] respectively.
The endomysium contains the basal lamina, encompassing individual cardiomyocytes,
and fibrillar collagens that form lateral connections between cells (Figure 2.2b). The function of
the endomysium is to support and align myocytes, aid in cell attachment, bring cardiomyocytes
together, and keep blood vessels close to cells for short diffusion distances of nutrients and
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
25/238
9
oxygen [17]. The perimysium is composed of fibrillar collagens, types I and III, in a weave that
connects the basal lamina of the endomysium to the large collagen fibers of the epimysium. The
thick collagen fibers of the epimysium are organized parallel to myofibrils protecting sarcomeres
from overstretch during relaxation [14]. In addition, this parallel organization allows forces to be
transmitted across the tissue layer during contraction to pump blood and aids in tissue elasticity
by pulling back on cardiomyocytes during relaxation. The unique organization of the
endomysium, perimysium, and epimysium, therefore, imparts mechanical integrity to the
myocardium necessary for the dynamic cardiac cycle.
Aside from the structural and functional role of the ECM during contraction and tissue
organization, the ECM also plays a critical role in transmitting signals to cardiac cells during
myocardial development, normal physiology, and in disease. The ECM, for example, provides
micro-structural cues to differentiating cardiomyocytes that regulate sarcomere self-assembly
and guide myofibrillogenesis [18, 19] and influences the rate of maturation of neonatal
cardiomyocytes [20]. Importantly, much of the regulatory information conveyed to cardiac cells
by the ECM is transmitted in the form of physical forces [21]. Cell attachment to the ECM is
primarily carried out by the transmembrane glycoprotein receptors, integrins, present at the cell
surface. Cardiac cells use integrins as mechanotransducers to sense mechanical stimuli within
the tissue leading to intracellular signaling and therefore a cellular response to stresses associated
with normal physiology and in pathological overload [21]. Mechanical forces can help maintain
normal cell shape and an oriented myofibrillar architecture, alter ECM production, gene
expression, cell size, phenotype, and expression and release of paracrine factors, increase
sensitivity to other signaling molecules, and upregulate cell-cell contacts important for the
electrical and mechanical properties of the tissue [15, 22-28]. The response of different cardiac
cells to mechanical forces is very complex and depends on the specific cell type and physical
state of the tissue. Taken together, the ECM is far more than a passive component of the
myocardium but rather an active structural, functional and regulatory component of this tissue.
2.1.3 Reparative Response of the Heart to Myocardial Infarctions
Cardiac tissue has a high demand for oxygen due to the high energy consumption
associated with muscle contraction. To ensure that active cardiomyocytes obtain a sufficient
supply of oxygen required to maintain aerobic respiration, the cells are in close proximity to
blood vessels of the coronary arteries. Reduced blood flow in the coronary arteries renders the
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
26/238
10
heart muscle susceptible to ischemic injury. Coronary artery disease refers to degenerative
changes in the coronary circulatory supply resulting in a reduction in the blood flow to the tissue
[29]. Sudden occlusion of the coronary arteries, or a myocardial infarction (MI), occurs in
severe cases of coronary artery disease leading to myocardial necrosis [29].
Several phases characterize the hearts wound repair process after a myocardial
infarction: cardiomyocyte death, acute inflammation, formation of granulation tissue, ventricular
remodeling, and the formation of organized collagen-rich scar tissue (reparative fibrosis) [30].
In reparative fibrosis, fibroblasts and myofibroblasts, both resident and recruited to the infarct
region, synthesize and deposit ECM proteins including collagen types I, III, and V [28]. While
ECM constituents are being produced, proteases are continuously degrading the ECM to allow
cell migration and remodeling to take place [30]. The end result of the reparative fibrosis is an
adaptive response that maintains the structural integrity of the ventricle, but replaces the injured
myocardial tissue with a dynamic non-contractile scar tissue [31]. Reactive fibrosis, which
occurs in the absence of cell loss around the insulted region, occurs alongside the reparative
fibrosis leading to enhanced myocardial stiffening, arrhythmias, and reduced systolic function
[28, 31]. The hearts response to myocardial insult, therefore, is a reparative one characterized by
a loss of contractile function and myocardial fibrosis. The initial myocardial injury and
secondary effects of the hearts reparative process leads to disruption of the normal cellular and
extracellular composition and organization and the progression to heart failure.
2.2 Matrix Metalloproteinases and their Role in Heart Remodeling andDisease
The matrix metalloproteinases (MMPs) are a family of zinc-binding endoproteinases that
are the driving force behind myocardial matrix remodeling. All MMPs share several functional
features; they degrade ECM components, are activated when zinc is removed from the active
site, need calcium for stability, function at neutral pH, and are inhibited by specific tissue
inhibitors of metalloproteinases (TIMPs) in a 1:1 stoichiometric ratio [32]. MMPs are localized
in the cardiac interstitial space as latent pro-enzymes requiring activation by autoproteolysis, the
serine protease plasmin, oxidized glutathione, or other activated MMPs [33, 34]. Several MMPs
and TIMPs have been identified in the heart and help to maintain normal ECM turnover. In the
developing mouse heart, Nutell et al. [35] found that different levels of MMP-2, MMP-3, MMP-
8, MMP-9, MMP-11, MMP-12, MMP-13, MMP-15, MMP-19, MMP-23, MMP-24, and MMP-
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
27/238
11
28 along with TIMP-1, TIMP-2, TIMP-3, and TIMP-4 are all expressed. Similarly, MMP-1,
MMP-2, MMP-3, MMP-9, MMP-13, and MMP-14 have all been found in human myocardium
[36], and it is likely that others are also expressed. The interplay between these different
proteases and inhibitors creates a balance that contributes to normal myocardial ECM structure
and function. Cardiac pathologies, however, cause an imbalance in these enzymes and play a
role in myocardial collagen accumulation, collagen fibril disruption, myocyte loss, and altered
spatial orientation of cells and intracellular components.
2.2.1 MMP Expression Following Myocardial Infarctions and in HeartFailure
Following a myocardial infarction and in the progression of heart failure, myocardial
fibrosis and remodeling occur due to an imbalance in ECM production, MMP activity, and TIMP
expression [37]. This dysregulation in ECM turnover is a response of cardiac and inflammatory
cells triggered by many different factors including various inflammatory cytokines, growth
factors, and mechanical stresses associated with myocardial injury and pressure overload [37-
39]. Although the exact expression profiles of MMPs and TIMPs depends on the cause, severity,
and stage of heart disease (Figure 2.3), significant increases in MMP-1, MMP-2, MMP-9, MMP-
13, and MMP-14 and reduced levels of TIMP-1, TIMP-3, and TIMP-4 have been observed in
human patients with heart disease [37]. In a study by Webb et al. [40], temporal profiling of
various plasma MMP and TIMP levels was performed on patients following a MI demonstratingthe dynamic changes in MMP and TIMP expression patterns over time. Although in this study
an elevation of MMP-9 levels was linked to left ventricular dilation and adverse myocardial
remodeling months after the initial insult, the exact contribution of the different MMPs and
TIMPs expressed in the progression of heart failure is difficult to determine. Genetic mouse
models, however, have revealed important insight into the role of some of these MMPs and
TIMPs in heart disease. Kim et al. [41] constitutively expressed MMP-1 in the heart and found
compensatory myocyte hypertrophy at 6 months and a loss of cardiac interstitial collagen
concurrent with a marked deterioration of systolic and diastolic function at 12 months. This
study directly demonstrated that disruption of the extracellular matrix in the heart reproduces the
changes observed in the progression of heart failure. Similarly, the targeted deletion of MMP-2
[42] and MMP-9 [43] in knockout mice after an induced myocardial infarction attenuated left
ventricular dilation and ventricular remodeling and improved cardiac function compared to wild
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
28/238
12
type controls. These studies clearly implicate the role of MMP-1, MMP-2, and MMP-9 in
adverse myocardial remodeling in the progression to heart failure following a MI and are being
investigated as potential targets for pharmaceutical intervention [38].
Figure 2.3: Alterations in MMP and TIMP levels in human heart disease. Italic lower case letters depict mRNA
levels, capital letters indicate protein levels, , and represent increase, decrease, and no change, respectively.
* denotes circulating plasma levels. Image used with permission from Kassiri and Khokha [37].
2.2.2 Cleavage Sites of ECM Proteins, Peptides and Biomaterials by MMPs
A priori knowledge of the expression profiles and key proteases involved in ECM
remodeling following a myocardial infarction and in heart failure not only identifies key targets
for therapeutic intervention but also allows the development of techniques that exploit the
presence of those enzymes to achieve a particular goal. In tissue engineering, specific sequences
have been incorporated into biomaterial scaffolds that make them susceptible to degradation by
MMPs expressed in various events, such as ECM remodeling, cell migration, angiogenesis, and
wound healing. Biological materials derived from the ECM inherently have these sequences
contained within them and therefore may naturally be degraded by the MMPs. Synthetic
materials, however, may also be developed to incorporate specific MMP-sensitive sequences
conferring unique biological function to these synthetic polymers. When designing novel
enzyme-degradable biomaterials for cardiac tissue engineering, MMP-1, MMP-2, and MMP-9
are rational targets due to their role in heart disease.
After being activated, MMP-1 functions by cleaving various collagens at specific sites in
the native triple helical structure. MMP-1 cleaves collagen type I at Gly775-Ile776 in the 1(I)
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
29/238
13
chain and Gly775-Leu776in the 2(I) chain, collagen type II at Gly775-Leu776in the 1(II) chain,
and collagen type III at Gly775-Leu776 in the 1(III) chain [44, 45]. This specific and
characteristic cleavage of collagens at approximately the length of the collagen fiber from the
N-terminus leads to two fragments that lose stability and unfold to produce single -chains
called gelatins. Further breakdown of the gelatins and short peptides is not as specific as in the
intact collagen but is traditionally carried out by the gelatinases, MMP-2 and MMP-9, and may
occur at other Gly-Leu and Gly-Ile sites in the polypeptide chains [45]. In addition to MMP-1
breaking down collagens and MMP-2 and MMP-9 degrading gelatins, each of these enzymes are
able to cleave a broad range of substrates, including various collagens, gelatins, elastin,
proteoglycans, regulatory molecules, and other ECM proteins [45-48]. An important result of an
early MMP-1 study was that specificity with this enzyme is largely independent of substrate
conformation and reflects the cleavage site and surrounding amino acid sequences in the native
proteins [49]. As a result, much information has been generated on the specificity requirements
of MMPs by measuring the kinetics of cleaving various short peptide sequences [45]. It was
determined that the recognition of MMPs is based on short peptide sequences up to seven amino
acids in length, three or four amino acids on either side of the scissile bond, and the rate of
cleavage by specific MMPs is determined by the sequence chosen [45]. Several peptides cleaved
by many MMPs do so at Gly-Leu and Gly-Ile sites, mimicking sequences cleaved in native ECM
proteins [45], thus identifying potential sequences and target bonds that may be used inbiomaterial design.
Pioneering work by West and Hubbell [50] incorporated short peptide sequences into
synthetic hydrogel systems making them susceptible to degradation by the cell secreted
proteases, collagenase and plasmin. Hydrogels were developed using the sequences Ala-Pro-
Gly-Leu, with cleavage between the Gly and Leu residues, and Val-Arg-Asn, with cleavage
between the Arg and Asn residues, for degradation by collagenase and plasmin respectively [50].
Subsequent work by Guan and Wagner [51] involved the formation of an elastase sensitive
segmented polyurethane by using the tri-peptide Ala-Ala-Lys in the backbone structure of the
polymer. A critical finding in this study was incorporation of the cleavage site of elastase alone
(Ala-Ala) was enough to confer biological function to the material. Taken together, these
findings suggest that targeting the Gly-Leu and Gly-Ile cleavage sites of MMP-1, MMP-2, and
MMP-9 may confer protease-sensitivity to synthetic biomaterials and may aid in the rational
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
30/238
14
design of biomaterials for cardiac tissue engineering that seek to exploit the presence of these
enzymes.
2.3 Regenerative Approaches to Repair the Heart
The need for new therapeutic options to treat an infarcted or failing heart has motivated
researchers to establish techniques to repair, replace, or augment the function of the diseased or
injured tissue. Current techniques being investigated to achieve this fall into a few broad
categories: 1) induction or stimulation of endogenous mechanisms of cardiac repair and
regeneration; 2) the direct transplantation of cells into the damaged tissue; or 3) the use of
biomaterials on their own or in combination with 1 and/or 2 to engineer cardiac tissue either ex
vivofor subsequent transplantation or in situ. Each of these different approaches has potential in
the treatment of heart disease, but it is important to distinguish improvements in physiological
function that occur due to myocardial regeneration and those that occur due to other
mechanisms, such as improved vascularization, reduced scar size, and enhanced cell survival.
Murry et al. [52] recommended that to prove heart regeneration has been achieved, structural,
physiological, and molecular end points must be used to demonstrate the technique has resulted
in newly created cardiomyocytes that are electromechanically connected to host myocardium and
contribute to cardiac function. Any improvement to cardiac function is important for the
treatment of heart disease and warrants extensive investigation, but only the approaches that may
lead to true myocardial regeneration will be discussed here.
2.3.1 Inducing Endogenous Mechanisms in Heart Repair
Adult cardiomyocytes have traditionally been considered terminally differentiated cells
that are incapable of proliferating to any significant degree and are therefore unable to regenerate
an injured or diseased heart. Although the inability of the heart to regenerate considerably on its
own appears acceptable, work performed in this field has challenged the view that the heart does
not regenerate at all and stem and progenitor cells that have cardiomyogenic potential have been
identified in the adult heart. Beltrami et al. [53] isolated Lin- c-kitPos cells from the adult rat
heart that were self renewing, clonogenic, and multipotent, giving rise to cardiomyocytes,
smooth muscle cells, and endothelial cells. This same group subsequently identified and isolated
similar c-kitPos
cardiac stem cells from human hearts, which mimicked the properties of those
from the rat heart, and demonstrated these cells could form new myocardium in infarcted animal
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
31/238
15
models independent of cell fusion [54]. Oh et al. [55] demonstrated the presence of Sca-1+(c-
kitNeg
) cardiac progenitor cells in the adult murine heart that can differentiate into cells
expressing several cardiac-specific markers in vitro. In response to a myocardial infarction,
endogenous Sca-1+ cells were not mobilized but transplanted Sca-1
+ cells homed and
differentiated into cardiac cells in the infarct border zone, half of which fused with host
cardiomyocytes [55]. Matsuura et al. [56] similarly isolated Sca-1+cells from the adult murine
heart and differentiated these cells in vitro into cardiomyocytes that expressed cardiac
transcription factors and contractile proteins, displayed sarcomeric structures, and contracted
spontaneously. Sca-1+ cardiac progenitor cells have also recently been isolated from adult
human hearts and demonstrate the same potential for deriving cardiomyocytes in vitroas their
mouse equivalents [57]. Martin et al. [58] used an ATP-binding cassette transporter, Abcg2, as a
marker for cardiac side population cells found in the developing and adult murine heart that may
function as a progenitor cell population in developing, maintaining, and repairing the heart. In
addition, Isl1+cardiac progenitor cells that give rise to cardiomyocytes, smooth muscle cells and
endothelial cells have also been identified in embryonic and postnatal hearts, but it remains
unclear what potential they have in the adult heart [59, 60]. Taken together, several studies have
identified different resident cardiac stem and progenitor cells in an adult heart that may have
potential in regenerating injured myocardium. Evidence has been presented that suggests some
of these cells are activated by injury and inherently contribute to heart regeneration [61], but if it
is occurring, it is not significant on its own to regenerate the tissue. Thus, the next step in
achieving myocardial repair using the bodys endogenous regenerative capacity is determining
how to induce these cells to regenerate significant portions of the injured heart.
2.3.2 Cellular Cardiomyoplasty
Cellular cardiomyoplasty, or cell transplantation, is a technique that seeks to promote
cardiac regeneration by introducing cells either directly to the site of injury or to the blood
supply for subsequent homing and integration. This cell-based approach attempts to directlyaddress the fundamental consequence of a myocardial infarction and a critical component of
heart failure progression; the loss of cardiomyocytes. By introducing cells into the injured heart,
it was hypothesized that the new cells could adapt to the unique myocardial microenvironment
and replace the function of the dead cardiomyocytes. Skeletal myoblasts were the first cell type
to be chosen for transplantation into an infarcted heart and numerous cell types have
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
32/238
16
subsequently been investigated including fetal and neonatal cardiomyocytes, bone marrow-
derived stem cells, endothelial progenitor cells, resident cardiac stem cells, and both mouse and
human embryonic stem cells. Table 2.1 provides a full list of potential cells for myocardial
repair along with some advantages and disadvantages of each for this application. Although
several of these cell types have been shown to improve cardiac function when transplanted in an
infarcted heart and have prompted clinical trials, relatively few of them result in true myocardial
regeneration. Using the recommended guidelines for defining heart regeneration by Murry et al.
Table 2.1: List of cell types considered for cardiac repair. Used with permission from Chen et al. [62].
Cell Source AutologousEasily
Obtainable
Highly
Expandable
Cardiac
Myogenesis
Clinical
TrialSafety
Somatic Cells
FetalCardiomyocytes
No No No Yes No No
Skeletal Myoblasts Yes YesDepends on
ageNo Yes
Yes,
arrhythmias
Smooth Muscle
CellsYes Yes Yes No No No
Fibroblasts Yes Yes Yes No No No
Stem and
Progenitor Cells
Mesenchymal
Stem CellsYes No
Depends on
ageDebated No
Yes, fibrosis
calcification
EndothelialProgenitor Cells
Yes YesDepends on
ageDebated No
Yes,calcification
Crude Bone
Marrow CellsYes Yes
Depends on
ageDebated Yes
Yes,
calcification
Umbilical CordCells
No Yes Yes Debated No No
Hematopoietic
Stem CellsYes Yes Yes Debated No Yes
Embryonic Stem
CellsNo No Yes Yes No
Yes, potential
teratomas
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
33/238
17
[52], the ideal cell source for cellular cardiomyoplasty should meet the following criteria: easy to
isolate and expand in vitro; achieve electrical and mechanical integration with host myocardium;
contribute to the structural organization and contractile performance of the heart; and be able to
attain an adult cardiomyocyte phenotype. The literature on cellular cardiomyoplasty is quite
large, so only a brief discussion of the cell types that may lead to true myocardial regeneration
will be presented.
2.3.2.1 Fetal and Neonatal Cardiomyocytes
To replace the lost cells associated with a MI, cardiomyocytes are the logical cell choice
for cell-based therapies. Early proof-of-principle work demonstrated transplanted fetal and
neonatal cardiomyocytes can form stable grafts in the myocardium that are electromechanically
connected to host cells via intercalated discs in normal and infarcted hearts [63-65]. Stable
integration of these cells into injured hearts resulted in decreased scar tissue formation, increased
angiogenesis and vascularization, reduced dilatation, and improved ventricular function as
measured using several different techniques [66-71]. Fetal and neonatal cardiomyocytes,
therefore, appear to meet several of the criteria as an ideal cell type for cellular cardiomyoplasty:
electromechanical coupling with host; structural and functional contribution to myocardium; and
the potential of an adult cardiomyocyte phenotype. Importantly, these transplantation studies
provide significant evidence to support the hypothesis that true myocardial regeneration may be
achieved in an infarcted heart and offers continued hope for the development of regenerative
therapeutic options for myocardial repair. Unfortunately, there are a few caveats associated with
the transplantation of fetal and neonatal cardiomyocytes preventing their use in the clinical
setting. First and foremost, human fetal and neonatal cardiomyocytes cannot be used due to
ethical considerations associated with their origin and consequences of harvesting. While
meeting most of the criteria of an ideal cell source for this work, they fall short on being easy to
isolate and expand. Second, only a limited number of transplanted cardiomyocytes engrafted
and survived in the injured heart resulting in the replacement of only a small fraction of theinfarct scar [72, 73]. The low cell engraftment number may be due to cardiomyocyte death
caused by ischemia [73]. These results suggest that a fundamental limitation in cellular
cardiomyoplasty is the delivery, engraftment, and survival of a sufficient number of cells into the
heart to replace the lost cardiac function. Methods to overcome this obstacle may be provided
through the use of biomaterials and will be discussed in greater detail below.
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
34/238
18
2.3.2.2 Embryonic Stem Cell-Derived Cardiomyocytes
Embryonic stem cells (ESCs) have the unique advantage over adult stem cells in that they
have the potential of providing a potentially unlimited source of new cardiomyocytes.
Embryonic stem cells are derived from the inner cell mass of the blastocyst stage developing
mammalian embryo [74, 75]. ESCs derived from mice (mESCs) are pluripotent cells capable of
long term undifferentiated proliferation in vitrowhile retaining the developmental potential of
forming all three embryonic germ layers; endoderm, mesoderm, and ectoderm [76]. Human
ESCs (hESCs) have similar capabilities as mESCs but have the unique advantage of also being
able to give rise to the trophoblast, an extra-embryonic tissue [75, 77]. Being able to give rise to
mesodermal cells, mESCs and hESCs are capable of differentiating into cardiomyocytes with
similar characteristics as those found in vivo and therefore provide a potential source of new
cardiomyocytes for cardiac repair [78, 79]. The potential use of ESCs in myocardial
regeneration, however, requires several criteria be met: 1) a sufficient number of starting ES
cells; 2) efficient and directed differentiation into cardiac progenitor cells or cardiomyocytes; 3)
high production of ESC-derived cardiac progenitors or myocytes; 4) a highly pure population of
desired cells; and 5) resulting phenotype and function similar to adult cardiomyocytes. To be
used in the clinical setting, these criteria must be proven with hESCs. Information and
established techniques for culturing, differentiating, and genetically manipulating murine ESCs,
however, make them a useful model for studying the potential of embryonic stem cell-derived
cardiomyocytes (ESCDCs) in cardiac regeneration. In relation to work conducted in this thesis,
this discussion will mostly focus on mESCs.
To help identify the potential of using ESCs for cellular cardiomyoplasty, several
investigators looked at directly injecting undifferentiated mESCs into the myocardium to test if
the unique microenvironment can drive the differentiation of the cells towards the cardiac
lineage without any adverse affects. Behfar et al. [80] found that transplanted undifferentiated
mESCs differentiated into cardiomyocytes and became functionally integrated into normal and
infarcted myocardium. This work suggests that the host myocardium creates an environment
that can commit undifferentiated mESCs to a specific cardiac lineage and the functionally
integrated cells can lead to an improvement in cardiac function. Similar studies by Min et al.
[81, 82] demonstrated the survival, engraftment, and differentiation of mESCs into mature
cardiac myocytes that attenuated left ventricular hypertrophy, reduced infarct size, improved left
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
35/238
19
ventricular contractility, and increased angiogenesis within the infarcted region. While these
results seem promising for the use of undifferentiated ESCs directly, Nussbaum et al. [83] found
that normal or infarcted hearts do not provide the appropriate cues to guide undifferentiated
mESCs towards a cardiomyocyte fate, but rather leads to teratoma formation and subsequent
rejection in immunocompetent mice. Other groups have similarly found teratoma formation is
the consequence of transplanting undifferentiated mESCs in the heart and other tissues and
represents a major concern for their clinical use [84-86]. As a result of this controversy, a more
restricted ESC-derivative may be more appropriate for use in these studies.
2.3.2.2.1 Differentiation of Murine Embryonic Stem Cells intoCardiomyocytes
Murine ESCs are maintained in an undifferentiated state by coculturing with an
embryonic fibroblast (MEF) feeder layer or by the soluble factor leukemia inhibitory factor (LIF)
and can potentially lead to indefinite self renewal and the generation of a large number of these
cells [87]. Removal of LIF from the culture medium induces differentiation into multiple cell
types and is correlated with a change in expression of the transcription factor Oct-4, a marker of
undifferentiated cells [88]. In vitro differentiation is accomplished via the formation of
aggregated ESCs, called embryoid bodies (EBs), in the absence of LIF leading to the formation
of a number of specialized cells, including cardiomyocytes [89].
Cardiomyocytes derived from mESCs exhibit varying levels of development, whichmimics in vivo differentiation, and appears to be a function of time in culture [89]. In early
beating EBs, mESCDCs may appear as small, round cells with sparse and irregular myofibrils or
more rod-shaped with parallel bundles of myofibrils and A and I bands [78]. As culture time
progresses, cell size increases, ranging greatly from neonatal (diameter ~7-9 m and length ~20-
45 m) to adult dimensions (diameter ~10-30 m and length ~80-150 m), myofibrils become
densely packed and well organized, and sarcomeres have defined A, I, and Z bands [78]. In
addition, the more developed cells form nascent intercalated discs, with desmosomes, fascia
adherens junctions and gap junctions, and the gap junctions are functional as demonstrated
through dye transfer studies [78]. The cardiac gene expression pattern of mESCDCs follows the
developmental pattern of cardiomyocytes in vivowith the expression of GATA-4 and Nkx2.5
observed prior to ANP, myosin light chain-2v (MLC-2v), and -myosin heavy chain, Na+-Ca
2+
exchanger, and phospholamban [89]. Sarcomeric protein expression in mESCDCs also follows a
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
36/238
20
progressive developmental pattern observed in vivo [89]. In addition, early mESCDCs express
slow skeletal muscle troponin I, a greater proportion of -myosin heavy chain, and have a high
sensitivity to calcium similarly seen in embryonic cardiomyocytes [90-92]. Increased culture
time leads to a shift from these fetal isotypes to cardiac troponin I, -myosin heavy chain, and
decreased sensitivity to Ca2+
more characteristic of mature neonatal and adult cardiomyocytes.
The specialized cardiomyocyte types undergo a shift from pacemaker-like cells early to purkinje-
like cells in the intermediate and atrial and ventricular cells later on [93]. Functionally, the
mESCDCs spontaneously contract, exhibit many features of the excitation-contraction coupling
mechanism found in isolated fetal and neonatal cells, express all major cardiac-specific ion
channels, and may respond to pharmacological agents at later stages of development [89, 93].
Taken together, mESCs can differentiate into cardiomyocytes that initially appear as embryonic-
like cells, but with increased time in culture mature and express more neonatal and adult-like
phenotypes.
Cardiomyocytes spontaneously form in differentiating EBs, but the actual yield of
cardiomyocytes derived from mESCs depends on a number of factors including starting EB size,
culture medium and conditions, ES cell line being used, and time of EB plating [94]. EBs
resemble early post-implantation embryos and the signaling events that drive differentiation into
the different specialized cell lineages loosely mimic those that occur during normal development.
As a result, several extrinsic factors that play a role in cardiomyogenesis in vivo similarly
promote cardiomyocyte formation within EBs. Numerous growth factors and signaling proteins
have been identified that help drive differentiation towards the cardiac lineage in a concentration
and temporal manner including TGF-1, bone morphogenic protein (BMP)-2, BMP-4, insulin-
like growth factor-1, fibroblast growth factor, hepatocyte growth factor, platelet-derived growth
factor, activin, oxytocin, Wnt/-catenin inhibition, and erythropoietin [95, 96]. Similarly,
synthetic compounds, such as dimethyl sulfoxide, 5-azacytadine, ascorbic acid, retinoic acid,
opioid, and dynorphin, and free radicals and reactive oxygen species have also been shown to
stimulate cardiomyogenesis [95, 96]. In addition, the physical microenvironment that the
mESCs are placed in may contribute to driving differentiation towards the cardiac lineage.
Features such as matrix composition, topography, 3-D structure, rigidity, and mechanical
stimulation may influence mESCDC yields [97]. Coculture with various cells, such as visceral
endoderm-like cells, may be another method for promoting cardiomyocytes from mESCs [98].
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
37/238
21
Taken together, the identified factors may help drive cells towards the cardiac lineage and
increase the percentage of cardiomyocytes, but have not been able to yield a large and pure
population of ESC-derived cardiac progenitor cells or cardiomyocytes, a requirement for use in
many regenerative applications.
2.3.2.2.2 Large-scale Production of a Pure Population of Embryonic StemCell-Derived Cardiomyocytes
One requirement for the successful implementation of ESCs for regenerating the
myocardium is a large and pure population of cardiac progenitors or fully differentiated
cardiomyocytes. As discussed above, any undifferentiated ESCs used in these applications may
lead to undesirable teratoma formation. Similarly, even with the addition of factors to drive cells
towards the cardiac lineage, ESC differentiation results in a mixture of cell types that could have
deleterious consequences when transplanted into the heart.
The recognized need for obtaining a pure population of cells has led to a few novel
techniques for selecting ESCDCs. The first approach involves genetic manipulation of the ESCs
to introduce antibiotic resistance to ESCDCs. Fields group developed a simple system that
inserted a fusion gene carrying two transcriptional units into mESCs [99]. The fusion gene
contained a phosphoglycerate kinase promoter driving hygromycin resistance gene (pGK-hydror)
to select for mESCs that were stably transfected and a -myosin heavy chain promoter driving an
aminoglycoside phosphotransferase gene (MHC-neor
), which allowed for the selection ofmESCDCs by adding the neomycin analog geneticin (G418) to culture medium. The mESCDCs
selected by this method were >99% pure and expressed markers of highly differentiated cardiac
cells [99]. Kolossov et al. [85] used a similar approach to get a highly purified mESCDC
population (>99%) by having the -myosin heavy chain promoter drive both a puromycin
resistance gene and a green fluorescent protein (GFP) gene for purification and identification of
the cells. Other groups have also used this genetic selection method for purifying
cardiomyocytes from mESCs and hESCs [100-102]. A second approach to purifying ESCDCs is
to label cell surface markers with fluorescent or magnetic tags and to use fluorescence activated
cell sorting (FACS) or magnetic-activated cell sorting. If appropriate cell surface markers
become available, this approach is advantageous as it avoids any need to genetically modify the
cells. Cell surface markers for cardiac progenitor cells or cardiomyocytes are currently not
known [103], but the molecular signature of ESCDCs is being explored [104] and may lead to
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
38/238
22
potential markers to be used in this purification scheme. Still, the proof of concept for purifying
mESCDCs by FACS has been demonstrated by Muller et al. [105] using a transgenic mESC line
expressing GFP under the cardiac chamber-specific promoter MLC-2v. A Percoll gradient
separation followed by FACS resulted in a >97% pure cardiomyocyte population and
electrophysiological tests identified the cells were preferentially ventricular-like [105]. Hidaka
et al. [106] also used FACS to purify Nkx2.5 positive cardiac progenitor cells from mESCs and
showed the resulting cells differentiated into sinoatrial node, atrial, or ventricular-like cells.
Transgenic GFP expression has been used to identify other cardiac progenitor cells or specialized
cardiomyocyte types including pacemaker, atrial, and ventricular cells [80, 107, 108], suggesting
these cells may also be separated by the FACS approach. Other methods to help purify ESCDCs
are a Percoll gradient separation and manually picking out beating cells, but both methods only
lead to an enriched culture of mESCDCs and these heterogeneous cell populations may inhibit
clinical acceptance [103].
The large number of cells required for use in cell-based regenerative strategies for
myocardial repair has motivated researchers to develop systems for the large-scale production of
ESCDCs. The Zandstra group has been particularly interested in developing and optimizing
bioreactor parameters for the generation of large quantities of ESCDCs. In an early study,
Zandstra et al [109] aggregated MHC-neor/pGK-hygro
rmESCs in static culture for 4 days and
transferred the EBs to a spinner flask system for subsequent growth and differentiation. On day
9 after initiating differentiation, medium was supplemented with G418 and retinoic acid to select
for and drive differentiation towards cardiomyocytes. A relatively pure mESCDC population
was harvested from the spinner flasks on day 18 with no undifferentiated mESCs and the cells
were spontaneously beating and expressed characteristic markers of mESCDCs [109].
Importantly, this system allowed the generation of ~1.4 x 107 cells in a 250 ml spinner flask
using the CM7/1 mESC line, thus identifying the large-scale production of mESCDCs.
Subsequent work by this group optimized cell and bioreactor conditions to produce even greater
numbers of ESCDCs. Bauwens et al. [110] used a similar approach but encapsulated the EBs in
a hydrogel to prevent aggregation and generated nearly 24 times more ES cell-derived
cardiomyocytes (~3.15 ESCDC per input mESC) than in unencapsulated controls (~0.15 ESCDC
per input ESC) after 9 days of differentiation and 5 days of selection using the D3 mESC line.
These mESCDC yields were increased even further (~3.77 mESCDC/ESC) by perfusion feeding
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
39/238
23
the bioreactor system and culturing under hypoxic conditions (~4% O2 compared to normoxic
levels of ~20%). Recently, Niebruegge et al. [111] directly inoculated bulb-shaped glass spinner
flasks with 2 x 105 CM7/1 mESCs per ml of culture medium for EB formation within the
bioreactor system. Optimization of several parameters including addition of retinoic acid at day
7 instead of day 9, starting selection at day 11 not day 9, and changing 50% of medium every
other day instead of every day resulted in a 4.3 fold increase in number of mESCDCs (~7.6
ESCDC/input mESC for optimized conditions vs. ~1.8 for unoptimized method) with a total of
19 x 107 cardiomyocytes in the 250 ml spinner flask [111]. Similar optimization efforts have
been reported by this group for the large scale generation of human ESCDCs. Factors such as a
homogenous starting EB size, a stirred suspension bioreactor, and hypoxic culture conditions are
more conducive of cardiomyocyte generation and improve hESCDC yields [112, 113].
Ultimately, the ability to derive a large and pure population of cardiomyocytes or cardiac
progenitor cells from ESCs is a critical step in identifying a cell source for regenerating the
myocardium.
2.3.2.2.3 Transplantation of Murine and Human ESC-derived Cells into theHeart
Several studies have been conducted to transplant murine and human ESCDC or cardiac-
committed ESCs for cellular cardiomyoplasty. In a study by Klug et al. [99], a highly pure
population of mESCDCs were transplanted into the heart and formed stable intracardiac graftsout to at least 7 weeks with a similar frequency of engraftment as fetal murine cardiomyocytes.
Menard et al. [114] transplanted cardiac-committed mESCs into infarcted sheep myocardium and
demonstrated the cells successfully engrafted into the infarct region, differentiated into mature
cardiomyocytes that were electrically connected to host myocardium, improved left ventricular
ejection fraction, and may avoid immune rejection. Kolossov et al. [85] injected purified
mESCDCs either alone or with an equal number of mouse embryonic fibroblasts into an
infarcted heart. It was determined that the mESCDCs had very low engraftment frequency when
injected on their own but was significantly increased when transplanted together with the
fibroblasts. The engrafted mESCDCs formed mature sarcomeric structures, electrically coupled
with host cardiomyocytes, did not develop into teratomas, contributed to ventricular force
contraction, and improved left ventricular function [85]. Thus, using mESCs to form cardiac
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
40/238
24
committed cells or a pure population of cardiomyocytes avoids the concern of teratoma
formation and may contribute to true myocardial regeneration.
While mESCs provide a good model for studying development, disease, and the potential
of ESCs in regenerative medicine, ultimately hESCs must be used if this technology is ever
going to transfer to the clinical setting. Several studies have been conducted using hESCs for
cellular cardiomyoplasty in animal models. Although the transplantation of undifferentiated
hESCs into an infarcted animal myocardium may help drive differentiation towards the
cardiomyogenic lineage without teratoma formation [115], the lessons learned from mESCs
along with the finding that these cells do form teratomas [116, 117] suggests hESCs must be at
least somewhat committed if they are going to gain clinical acceptance. As a result, recent work
has investigated transplanting hESC-derived cardiomyocytes (hESCDCs) or cardiac committed
hESCs into normal and infarcted animal hearts. Evidence has been provided that hESCDCs
survive, proliferate, form mature contractile structures, and electrically couple to host cells
following transplantation into healthy hearts of immunodeficient mice and rats [116, 118, 119].
In infarcted rodent myocardium, cardiac-committed hESCs and hESCDCs similarly appear to
survive and form a mature cardiomyocyte phenotype without any teratoma formation [116, 117,
119-122]. In addition, several of these investigations report an improvement to cardiac function
due to the engraftment of the cells [116, 117, 119, 121].
A few limitations associated with hESCDC transplantation studies include an inefficient
hESC differentiation into cardiomyocytes, a heterogeneous cell population, poor cell survival
after transplantation, and a transient contribution to cardiac function. In an attempt to overcome
some of these limitations, Laflamme et al. [121] treated a high density monolayer of
undifferentiated hESCs with two cytokines to drive differentiation towards the cardiac lineage
and enriched the hESCDCs by a Percoll gradient to get a ~83% pure cardiomyocyte culture (3:1
ratio of generated cardiomyocyte to input hESC). Transplantation of these cells along with a
mixture of prosurvival reagents into infarcted rat hearts resulted in large muscular grafts of
human myocardium in the central infarct region that coupled to host tissue and significantly
improved ventricular structure and contractile function compared to appropriate controls [121].
Despite long-term survival of the transplanted cells, the exact contribution they have on cardiac
function and their long-term benefit remains unclear [119, 123].
-
7/24/2019 Parrag Ian C 201006 PhD Thesis.pdf
41/238
25
While ESC appear to be the best candidate for regenerating the myocardium, ethical
considerations associated with harvesting human ESCs has limited wide-spread funding and use
of these cells. Induced pluripotent stem (iPS) cells may offer an alternative source of
cardiomyocytes [124] that may reduce ethical concerns, but this technology is still in a very early
stage with many obstacles to overcome before this option is viable. Regardless of the cell type
or source, cellular cardiomyoplasty on its own is limited by the delivery, engraftment, and
survival of cells in the heart. Interestingly, the prosurvival reagents used by Laflamme et al.
[121] for achieving improved long-term engraftment of hESCDCs included Matrigel, a
gelatinous protein mixture rich in structural extracellular matrix proteins and growth factors. In
this situation, Matrigel acted as a supportive matrix for the cells to adhere to, thus increasing cell
survival. The use of biomaterial scaffolds as a delivery vehicle for cells may overcome the
limitations of cellular cardiomyoplasty and may help to contribute to long-term clinically
relevant cardiac repair.
2.3.3 Cardiac Tissue Engineering
Cardiac tissue engineering is a technique that employs the use of biomaterials in
combination with cells and/or various signaling agents towards the development of viable tissue
constructs for regenerating the myocardium. Research in this area has expanded tremendously
over the past several years and continues to grow, but the goal remains the same and to date, a
few promising strategies have emerged. These approaches include using cells along with: 1)
biodegradable synthetic and natural-based scaffolds with pre-formed three-dimensional
structures; 2) biodegradable synthetic and natural-based materials with undefined structures; 3)
injectable biomaterials for in situ myocardial regeneration; and 4) temperature-responsive
biomaterials that act as a substrate for cell sheet formation. The focus of this thesis is on the first
of the four approaches, but a brief discussion of the other three will first be presented.
2.3.3.1 Myocardial Tissue Engineering Using Biomaterials with Undefined
StructuresCardiac cells have an endogenous ability to organize into native-like car
top related